# Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers

> **NCT03894124** · PHASE1 · COMPLETED · sponsor: **Chelsea and Westminster NHS Foundation Trust** · enrollment: 24 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

- **DRUG:** Doravirine

## Key facts

- **NCT ID:** NCT03894124
- **Lead sponsor:** Chelsea and Westminster NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-12
- **Primary completion:** 2019-07-25
- **Final completion:** 2019-08-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03894124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03894124, "Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03894124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*